Wednesday, at the age of 69, Al Biernat died following a seven-month battle with ALS and those who worked closest to him will ...

Pharmaust Limited (AU:NUZ) has released an update. Neurizon Therapeutics has announced promising preclinical results for its lead drug ...

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 ...

Water, a molecule essential for life, has unusual properties - known as anomalies - that define its behaviour. However, there are still many enigmas ...

Zac Brown Band's John Driskell Hopkins is turning his battle with ALS into a mission to help others: "When you're given a ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 26 years, gives his take on the ASX health care sector for the week and his ‘Powerplay’ stock ...

Restaurateur Al Biernat passed away on Wednesday, November 13, after being diagnosed with amyotrophic lateral sclerosis, also ...

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

ALS is a neurodegenerative disease that progressively paralyzes individuals as the brain loses the ability to communicate with the muscles. People living with ALS often experience a swift decline in ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury ...